BMY - Bristol-Myers Squibb
Bristol-Myers Squibb (NYSE: BMY) is a global biopharmaceutical company whose roots go back to 1858 when Edward Robinson Squibb, who wanted to improve the quality of medicine after he saw the quality of medicine available during the Mexican War.
Consequently he launched his own pharmaceutical laboratory in response to what he saw during that time.
Today Bristol-Myers Squibb continues in that tradition as it has as its core business to research, develop and provide medicines which will help "patients prevail over serious diseases."
The company had two lines of business: Pharmaceuticals and Nutritionals. The nutritional business is branded as Mead Johnson, and serves the infant and children's market through formula and other nutritional products.
At this time Bristol-Myers Squibb is looking to spin off the Mead Johnson Nutrition unit so it can focus on its core business of biopharmaceuticals. The company will retain an 80 percent interest after the IPO.
Key acquisitions include DuPont Pharmaceuticals Company, Adnexus Therapeutics and Kosan Biosciences
Bristol-Myers Squibb Company is headquartered in New York City.
Stock Symbol / Ticker: